These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36941537)

  • 21. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers.
    Takeda K; Liu S; Rong A
    Stat Med; 2022 Jan; 41(2):298-309. PubMed ID: 34697822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints.
    Zhao Y; Tang RS; Du Y; Yuan Y
    Biometrics; 2023 Jun; 79(2):1459-1471. PubMed ID: 35546501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.
    Gao G; Gajewski BJ; Wick J; Beall J; Saver JL; Meinzer C;
    Trials; 2022 Sep; 23(1):754. PubMed ID: 36068547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker-based Bayesian randomized clinical trial design for identifying a target population.
    Sugitani Y; Morita S; Nakakura A; Yamamoto H
    Stat Med; 2023 Jul; 42(16):2797-2810. PubMed ID: 37078122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.
    Curtis A; Smith B; Chapple AG
    Stat Med; 2022 Jul; 41(16):3164-3179. PubMed ID: 35429178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.
    Lee J; Thall PF; Msaouel P
    Stat Med; 2021 Oct; 40(24):5199-5217. PubMed ID: 34636054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive Enrichment Designs in Clinical Trials.
    Thall PF
    Annu Rev Stat Appl; 2021 Mar; 8(1):393-411. PubMed ID: 36212769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
    Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
    Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome.
    Vinnat V; Chevret S
    BMC Med Res Methodol; 2022 Feb; 22(1):54. PubMed ID: 35220954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive enrichment designs with a continuous biomarker.
    Stallard N
    Biometrics; 2023 Mar; 79(1):9-19. PubMed ID: 35174875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single arm two-stage studies: Improved designs for molecularly targeted agents.
    Dutton P; Holmes J
    Pharm Stat; 2018 Nov; 17(6):761-769. PubMed ID: 30112838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.
    Ballarini NM; Burnett T; Jaki T; Jennison C; König F; Posch M
    Stat Med; 2021 May; 40(12):2939-2956. PubMed ID: 33783020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MIDAS-2: an enhanced Bayesian platform design for immunotherapy combinations with subgroup efficacy exploration.
    Su L; Chen X; Zhang J; Yan F
    J Biopharm Stat; 2023 Dec; ():1-21. PubMed ID: 38131109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint.
    Guo B; Zang Y
    Stat Med; 2022 Mar; 41(7):1205-1224. PubMed ID: 34821409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.